Refreshed Website Guides Visitors on their Hemp CBD Journey with Multimedia Educational Resources, In-Depth Product Information and Improved Shopping… The market for products featuring hemp extracts is large and growing larger. However, safety concerns have been raised by medical and regulatory agencies. Post marketing surveillance of full spectrum hemp extract (FSHE) products manufactured and distributed by CV Sciences (CVSI) and traded under the …
CV Sciences, Inc. Launches Updated +PlusCBD™ Oil Website to Enhance User Experience and Drive Increased E-Commerce Sales
January 23, 2020 08:45 ET | Source: CV Sciences, Inc. CV Sciences, Inc.
San Diego, California, UNITED STATES
Refreshed Website Guides Visitors on their Hemp CBD Journey with Multimedia Educational Resources, In-Depth Product Information and Improved Shopping Tools
Company Well Positioned to Drive Rapid E-Commerce Channel Growth
SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the launch of its updated PlusCBD™ Oil website: www.pluscbdoil.com.
With a fresh look and feel, the updated PlusCBD™ Oil website offers visitors an enhanced user experience and walks them through their hemp CBD journey, with multimedia educational resources, enriched content, informative blog posts, groundbreaking research, in-depth product information and improved shopping tools, resulting in an easy-to-use customer experience. The updated website also offers an interactive quiz that recommends specific products to best suit a person’s unique needs and lifestyle.
“The refreshed PlusCBD™ Oil website is designed to add value to our new and existing customers throughout their entire CBD journey, from CBD education through product selection and checkout,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “During the past year, we have invested heavily in personnel, technology and digital marketing to support expansion of our direct-to-consumer e-commerce sales initiatives to ensure we are best positioned to drive growth through this important channel.”
Dowling continued, “E-commerce is our fastest growing channel, accounting for 21.6% of total sales in our most recently reported quarter, and we believe there is a significant growth opportunity for CV Sciences in e-commerce. We anticipate that the new PlusCBD™ Oil website will further enable CV Sciences to increase sales, enhance customer loyalty and capture greater market share in the hemp CBD category.”
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil products are sold at more than 5,700 retail locations through the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
Scott Van Winkle
Post Marketing Safety of Plus CBD™ Products, a Full Spectrum Hemp Extract: A 2-Year Experience
The market for products featuring hemp extracts is large and growing larger. However, safety concerns have been raised by medical and regulatory agencies. Post marketing surveillance of full spectrum hemp extract (FSHE) products manufactured and distributed by CV Sciences (CVSI) and traded under the brand PlusCBD™ was conducted over a 2-year period (2018-2019). The safety of these products was assessed by analyzing adverse events reports. From a total of approximately five million product units sold during the 2-year period, 1,429 (0.03%) adverse events (AE) were reported in 1,151 unique customers. Of those, only two were classified as serious AEs. For orally ingested products, the most common types of AEs reported were gastrointestinal (e.g. abdominal discomfort), while for topically applied products, the most reports mentioned dermatological symptoms (e.g. rashes). There has been no evidence of liver toxicity associated with CVSI products. Based on this longitudinal dataset, the products manufactured using CVSI’s proprietary processes are safe and well tolerated at the recommended doses.
Keywords: CBD; DSHEA; adverse event; cannabidiol; dietary supplement; full spectrum hemp extract (FSHE); nutravigilance; pharmacovigilance; serious adverse event; supplement safety.
Schmitz SM MD, MPH, Lopez HL MD, MS, Mackay D ND, Nguyen H BS, Miller PE BS. Schmitz SM MD, MPH, et al. J Diet Suppl. 2020;17(2):227-248. doi: 10.1080/19390211.2018.1513109. Epub 2018 Dec 4. J Diet Suppl. 2020. PMID: 30513022
Marinotti O, Sarill M. Marinotti O, et al. J Diet Suppl. 2020;17(5):517-526. doi: 10.1080/19390211.2020.1776806. Epub 2020 Jun 16. J Diet Suppl. 2020. PMID: 32543253
Cogan PS. Cogan PS. J Diet Suppl. 2020;17(5):527-542. doi: 10.1080/19390211.2020.1790710. Epub 2020 Jul 17. J Diet Suppl. 2020. PMID: 32677489
Clark JA, Humphries JE, Crean S, Reynolds MW. Clark JA, et al. Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):107-14. doi: 10.1002/pds.1874. Pharmacoepidemiol Drug Saf. 2010. PMID: 20014051 Review.
VanDolah HJ, Bauer BA, Mauck KF. VanDolah HJ, et al. Mayo Clin Proc. 2019 Sep;94(9):1840-1851. doi: 10.1016/j.mayocp.2019.01.003. Epub 2019 Aug 22. Mayo Clin Proc. 2019. PMID: 31447137 Review.
Lachenmeier DW, Walch SG. Lachenmeier DW, et al. F1000Res. 2020 Aug 26;9:1051. doi: 10.12688/f1000research.26045.2. eCollection 2020. F1000Res. 2020. PMID: 33082934 Free PMC article.